U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Positron Emission Tomography: Product Quality Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations   - 11/13/2023
  1. News & Events for Human Drugs

Public | Mixed

Event Title
Positron Emission Tomography: Product Quality Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations  
November 13 - 14, 2023

Date:
November 13 - 14, 2023
Day1:
Mon, Nov 13 8:00 a.m. - 05:00 p.m. ET
Day2:
Tue, Nov 14 8:00 a.m. - 12:00 p.m. ET
Location:
Event Location
White Oak Campus: The Great Room
Conference Center

10903 New Hampshire Ave
Building 31, Room 1503
Silver Spring, MD 20993
United States


Organized By:
Organizer

Location

FDA White Oak Campus
The Great Room
Conference Center
10903 New Hampshire Ave
Building 31, Room 1503
Silver Spring, MD 20993
United States

Co-Sponsors

Summary

This public workshop will be hosted by the Office of New Drugs (OND), Office of Regulatory Operations (ORO), and Division of Regulatory Operations for Specialty Medicine (DRO-SM). The purpose of this workshop is to provide a forum for the exchange of information and perspectives on the regulatory and compliance framework for Positron Emission Tomography (PET) drug manufacturing. Bringing all stakeholders together will improve the global understanding of regulatory and compliance topics associated with PET drug manufacturing.

Goals and Objectives 

  • Discuss regulatory compliance for the development and manufacturing of PET drugs and pathways for regulatory applications. 
  • Share perspectives from industry, academia, investigators and regulators on inspectional findings and trends. 
  • Provide information on the management of Part 212 inspections and maintenance of PET NDAs and ANDAs. 

Topics for Discussion

  • Trends on Inspections and Compliance 
  • Lifecycle Management of PET Drug Applications 
  • Product Quality Assurance 
  • Changing Landscape of PET Drugs: Labeling, Electronic Submissions

Meeting Agenda

Zoom Webinar

Contact

For additional details and questions contact the FDA’s CDER/OND/Public Meeting Support Team at ONDPublicMTGSupport@fda.hhs.gov. 

Event Materials

Title File Type/Size
PET Workshop Agenda pdf (220.87 KB)
PET Workshop Biographies pdf (1.04 MB)
PET Workshop Presentation pdf (13.19 MB)
Back to Top